Literature DB >> 16138108

The ascent of mouse: advances in modelling human depression and anxiety.

John F Cryan1, Andrew Holmes.   

Abstract

Psychiatry has proven to be among the least penetrable clinical disciplines for the development of satisfactory in vivo model systems for evaluating novel treatment approaches. However, mood and anxiety disorders remain poorly understood and inadequately treated. With the explosion in the use of genetically modified mice, enormous research efforts have been focused on developing mouse models of psychiatric disorders. The success of this approach is largely contingent on the usefulness of available behavioural models of depression- and anxiety-related behaviours in mice. Here, we assess the current status of research into developing appropriate tests for assessing such behaviours.

Entities:  

Mesh:

Year:  2005        PMID: 16138108     DOI: 10.1038/nrd1825

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  363 in total

1.  Measuring anxiety- and locomotion-related behaviours in mice: a new way of using old tests.

Authors:  Leanne M Fraser; Richard E Brown; Ahmed Hussin; Mara Fontana; Ashley Whittaker; Timothy P O'Leary; Lauren Lederle; Andrew Holmes; André Ramos
Journal:  Psychopharmacology (Berl)       Date:  2010-05-08       Impact factor: 4.530

Review 2.  Serotonin 5-HT7 receptor agents: Structure-activity relationships and potential therapeutic applications in central nervous system disorders.

Authors:  Marcello Leopoldo; Enza Lacivita; Francesco Berardi; Roberto Perrone; Peter B Hedlund
Journal:  Pharmacol Ther       Date:  2010-10-20       Impact factor: 12.310

3.  RGS inhibition at G(alpha)i2 selectively potentiates 5-HT1A-mediated antidepressant effects.

Authors:  Jeffery N Talbot; Emily M Jutkiewicz; Steven M Graves; Crystal F Clemans; Melanie R Nicol; Richard M Mortensen; Xinyan Huang; Richard R Neubig; John R Traynor
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-02       Impact factor: 11.205

4.  Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity.

Authors:  O Gunduz-Cinar; K P MacPherson; R Cinar; J Gamble-George; K Sugden; B Williams; G Godlewski; T S Ramikie; A X Gorka; S O Alapafuja; S P Nikas; A Makriyannis; R Poulton; S Patel; A R Hariri; A Caspi; T E Moffitt; G Kunos; A Holmes
Journal:  Mol Psychiatry       Date:  2012-06-12       Impact factor: 15.992

5.  Gene delivery to postnatal rat brain by non-ventricular plasmid injection and electroporation.

Authors:  Dmitry A Molotkov; Alexey Y Yukin; Ramil A Afzalov; Leonard S Khiroug
Journal:  J Vis Exp       Date:  2010-09-17       Impact factor: 1.355

6.  Modulation of behavioral networks by selective interneuronal inactivation.

Authors:  M J Schmidt; S Horvath; P Ebert; J L Norris; E H Seeley; J Brown; L Gellert; M Everheart; K A Garbett; T W Grice; R M Caprioli; K Mirnics
Journal:  Mol Psychiatry       Date:  2013-12-10       Impact factor: 15.992

7.  Characterization of rodent models of HIV-gp120 and anti-retroviral-associated neuropathic pain.

Authors:  Victoria C J Wallace; Julie Blackbeard; Andrew R Segerdahl; Fauzia Hasnie; Timothy Pheby; Stephen B McMahon; Andrew S C Rice
Journal:  Brain       Date:  2007-08-30       Impact factor: 13.501

Review 8.  A pharmacological analysis of mice with a targeted disruption of the serotonin transporter.

Authors:  Meredith A Fox; Anne M Andrews; Jens R Wendland; Klaus-Peter Lesch; Andrew Holmes; Dennis L Murphy
Journal:  Psychopharmacology (Berl)       Date:  2007-08-22       Impact factor: 4.530

Review 9.  Developmental rodent models of fear and anxiety: from neurobiology to pharmacology.

Authors:  Despina E Ganella; Jee Hyun Kim
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

10.  Fucoidan prevents depression-like behavior in rats exposed to repeated restraint stress.

Authors:  Bombi Lee; Insop Shim; Hyejung Lee; Dae-Hyun Hahm
Journal:  J Nat Med       Date:  2012-10-23       Impact factor: 2.343

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.